We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+10.17%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$15.4B
AUM Growth
+$2.08B
Cap. Flow
+$1.36B
Cap. Flow %
8.86%
Top 10 Hldgs %
54.82%
Holding
115
New
20
Increased
35
Reduced
31
Closed
11

Top Buys

Rank Stock Value
1
APC
Anadarko Petroleum
APC
+$702M
2
CELG
Celgene Corp
CELG
+$666M
3
WCG
Wellcare Health Plans, Inc.
WCG
+$459M
4
RHT
Red Hat Inc
RHT
+$333M
5
AGN
Allergan plc
AGN
+$138M

Top Sells

Rank Stock Value
1
TRU icon
TransUnion
TRU
+$181M
2
GOOG icon
Alphabet (Google) Class C
GOOG
+$173M
3
META icon
Meta Platforms (Facebook)
META
+$169M
4
BKNG icon
Booking.com
BKNG
+$157M
5
GG
Goldcorp Inc
GG
+$148M

Sector Composition

Rank Sector Weight
1 Healthcare 38.49%
2 Technology 17.66%
3 Communication Services 14.59%
4 Industrials 6.69%
5 Energy 5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVRD
76
Tvardi Therapeutics
TVRD
$24.8M
$20.5M 0.13%
+26,426
New +$18.6M
VYGR icon
77
Voyager Therapeutics
VYGR
$209M
$20.4M 0.13%
750,000
-250,158
-25% -$5.72M
CCXI
78
DELISTED
ChemoCentryx, Inc.
CCXI
$18.6M 0.12%
2,000,000
+500,000
+33% +$5.79M
PTGX icon
79
Protagonist Therapeutics
PTGX
$9.99B
$18.2M 0.12%
1,500,000
-290,000
-16% -$3.21M
TECX
80
Tectonic Therapeutic
TECX
$736M
$16.8M 0.11%
86,346
+11,346
+15% +$2.45M
NSTG
81
DELISTED
NanoString Technologies, Inc.
NSTG
$10.6M 0.07%
350,000
-50,000
-13% -$1.32M
EIGR
82
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$10.6M 0.07%
+33,333
New +$11.5M
VOYA icon
83
Voya Financial
VOYA
$8.86B
$10.2M 0.07%
185,000
– –
VCYT icon
84
Veracyte
VCYT
$3.4B
$9.98M 0.06%
+350,000
New +$8.74M
PHAS
85
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$9.93M 0.06%
+756,961
New +$9.28M
TWST icon
86
Twist Bioscience
TWST
$9.13B
$8.91M 0.06%
+307,055
New +$8.12M
SVRA icon
87
Savara
SVRA
$1.15B
$8.24M 0.05%
3,475,000
+1,050,000
+43% +$9.33M
QURE icon
88
uniQure
QURE
$3.36B
$7.82M 0.05%
+100,000
New +$6.37M
MIST icon
89
Milestone Pharmaceuticals
MIST
$131M
$6.79M 0.04%
+250,000
New +$5.16M
CYCN icon
90
Cyclerion Therapeutics
CYCN
$18.2M
$6.23M 0.04%
+27,204
New +$7.7M
PSNL icon
91
Personalis
PSNL
$1.96B
$5.02M 0.03%
+184,932
New +$5.23M
PFNX
92
DELISTED
Pfenex Inc.
PFNX
$4.04M 0.03%
600,000
– –
GCVRZ
93
DELISTED
Sanofi Contingent Value Rights
GCVRZ
$3.55M 0.02%
6,827,805
– –
AKRO
94
DELISTED
Akero Therapeutics
AKRO
$2.87M 0.02%
+150,000
New +$2.84M
APTX
95
DELISTED
Aptinyx Inc. Common Stock
APTX
$2.24M 0.01%
670,000
– –
GOSS icon
96
Gossamer Bio
GOSS
$75.6M
$2.22M 0.01%
100,000
-277,852
-74% -$5.32M
LRMR icon
97
Larimar Therapeutics
LRMR
$434M
$2.14M 0.01%
150,000
– –
ASMB icon
98
Assembly Biosciences
ASMB
$700M
$1.35M 0.01%
8,333
– –
ADPT icon
99
Adaptive Biotechnologies
ADPT
$4.15B
$1.21M 0.01%
+25,000
New +$1.11M
OXY icon
100
Occidental Petroleum
OXY
$61.3B
$1.01M 0.01%
+20,000
New +$1.13M
1 2 3
4
5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q2 2019 Portfolio in Review

As of Q2 2019, Thomas Steyer held 115 positions worth $15.4B, up 16% from $13.3B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Thomas Steyer deployed $1.36B of net new capital in Q2 2019, opening 20 new positions and adding to 35 existing holdings. Its largest new stake was Anadarko Petroleum: 10,465,000 shares worth $738M.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 30% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was TransUnion, an estimated $181M trimmed.

  • Thomas Steyer's largest Q2 2019 buy was Anadarko Petroleum: 10,465,000 shares worth $738M.
  • Thomas Steyer added most to Celgene Corp in Q2 2019, an estimated $666M increase.
  • Thomas Steyer's biggest Q2 2019 reduction was TransUnion, cutting an estimated $181M.
  • Thomas Steyer fully exited Goldcorp Inc in Q2 2019, selling an estimated $148M.
  • Thomas Steyer's ten largest holdings make up 55% of its $15.4B portfolio in Q2 2019.
  • Thomas Steyer opened 20 new positions and closed 11 in Q2 2019.
  • Thomas Steyer's portfolio value rose 16% quarter-over-quarter to $15.4B.

Based on Farallon Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.